The U.S. Food and Drug Administration (FDA) granted initial approval to Trastuzumab Deruxtecan (Enhertu) on December 20, 2019. This approval introduces a new therapeutic option to the market as a Type 1 New Molecular Entity.
Background
Trastuzumab Deruxtecan, also known by its brand name Enhertu (fam-trastuzumab deruxtecan-nxki), received its initial FDA approval as a Type 1 New Molecular Entity. This classification indicates that it is an active ingredient that has not been previously approved by the FDA. The sponsor for this drug is DAIICHI SANKYO.
What this means
The initial FDA approval of Trastuzumab Deruxtecan signifies a new therapeutic agent becoming available for clinical use. As a Type 1 New Molecular Entity, it represents a novel compound with a distinct chemical structure, offering a potentially new approach to treatment. This classification highlights its uniqueness, indicating that it is not a modification of an existing drug but rather a fundamentally new active ingredient. This approval provides clinicians with an additional option in their therapeutic arsenal, expanding the landscape of available treatments. The introduction of a new molecular entity can be particularly impactful, as it often addresses unmet medical needs or offers advantages over existing therapies, though specific indications are not detailed in the provided approval information.
Source
This information is based on the initial approval documentation from the U.S. Food and Drug Administration (FDA) for Biologics License Application (BLA) 761139. The approval event for Trastuzumab Deruxtecan (fam-trastuzumab deruxtecan-nxki) occurred on December 20, 2019, and is publicly accessible via accessdata.fda.gov.